DK0948319T3 - Indkapslede antistofdannende celler - Google Patents

Indkapslede antistofdannende celler

Info

Publication number
DK0948319T3
DK0948319T3 DK97954822T DK97954822T DK0948319T3 DK 0948319 T3 DK0948319 T3 DK 0948319T3 DK 97954822 T DK97954822 T DK 97954822T DK 97954822 T DK97954822 T DK 97954822T DK 0948319 T3 DK0948319 T3 DK 0948319T3
Authority
DK
Denmark
Prior art keywords
forming cells
encapsulated antibody
antibody
encapsulated
capsules
Prior art date
Application number
DK97954822T
Other languages
English (en)
Inventor
Marc Piechaczyk
Mireia Pelegrin
Mariana Marin
Robert Saller
Brian Salmons
Original Assignee
Bavarian Nordic As
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As, Centre Nat Rech Scient filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK0948319T3 publication Critical patent/DK0948319T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97954822T 1996-12-23 1997-12-18 Indkapslede antistofdannende celler DK0948319T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK149796 1996-12-23
PCT/EP1997/007120 WO1998027966A2 (en) 1996-12-23 1997-12-18 Encapsulated cells producing antibodies

Publications (1)

Publication Number Publication Date
DK0948319T3 true DK0948319T3 (da) 2004-02-09

Family

ID=8105461

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97954822T DK0948319T3 (da) 1996-12-23 1997-12-18 Indkapslede antistofdannende celler

Country Status (11)

Country Link
US (1) US6426088B1 (da)
EP (1) EP0948319B1 (da)
JP (2) JP4727768B2 (da)
AT (1) ATE252374T1 (da)
AU (1) AU6205998A (da)
DE (1) DE69725754T2 (da)
DK (1) DK0948319T3 (da)
ES (1) ES2208973T3 (da)
PT (1) PT948319E (da)
SI (1) SI0948319T1 (da)
WO (1) WO1998027966A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168339A1 (en) * 1997-01-20 2002-11-14 Marc Piechaczyk Biological material for treating a mammal by antibody gene transfer and pharmaceutical composition containing same
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
DE60137430D1 (de) * 2000-07-29 2009-03-05 Smith & Nephew Gewebeimplant zur wiederherstellung von knorpelgewebe
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
DE102005011367B4 (de) * 2005-03-11 2010-12-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Cellulosesulfat mit verbesserten Eigenschaften
MY175316A (en) 2011-01-25 2020-06-19 Austrianova Singapore Pte Ltd Protection of microbial cells from acidic degradation
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025929A (ja) * 1983-07-20 1985-02-08 ザ・スト−ル・リサ−チ・アンド・デイベロツプメント・コ−ポレ−シヨン カプセル化細胞、その製造方法および用途
ATE76331T1 (de) 1987-02-25 1992-06-15 Hoechst Ag Mikroenkapsulierung von biologisch aktivem material.
US5427935A (en) * 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5116747A (en) 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
US5997900A (en) * 1996-04-17 1999-12-07 Wang; Taylor G. Encapsulation system for the immunoisolation of living cells

Also Published As

Publication number Publication date
WO1998027966A2 (en) 1998-07-02
ATE252374T1 (de) 2003-11-15
EP0948319A2 (en) 1999-10-13
SI0948319T1 (en) 2004-04-30
ES2208973T3 (es) 2004-06-16
WO1998027966A3 (en) 1998-11-12
JP4727768B2 (ja) 2011-07-20
DE69725754T2 (de) 2004-08-19
US6426088B1 (en) 2002-07-30
AU6205998A (en) 1998-07-17
JP2001507344A (ja) 2001-06-05
PT948319E (pt) 2004-02-27
EP0948319B1 (en) 2003-10-22
JP2009013182A (ja) 2009-01-22
DE69725754D1 (de) 2003-11-27

Similar Documents

Publication Publication Date Title
NO962088D0 (no) Preparat for in vivo-produksjon av terapeutiske produkter
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
TR199802423T2 (xx) Konsantre antikor terkibi.
HUP0002831A3 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
WO1997019111A3 (es) Anticuerpos monoclonales anti-cd6 y sus utilizaciones
DK0948319T3 (da) Indkapslede antistofdannende celler
GB9806632D0 (en) Peptide factor
MX9602750A (es) Proteinas de la region v receptoras de antigenos de la celula t y metodos para la preparacion de las mismas.
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
ATE234636T1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
GR3020355T3 (en) Aminosulfonyl urea acat inhibitors
PL308074A1 (en) Derivatives of borone peptides, their production as well as their application in medical therapy
BR9506389B1 (pt) composto de silìcio, e, composição dietética, cosmética e terapêutica.
TR200401775T4 (tr) 3-Amino-1-Fenil-1H[1,2,4] triazol'ün dallanmış değiştirilmiş yeni amino türevleri, bunların imali için metot ve bunları içeren farmosötik (eczacılık) bileşimleri
ZA983239B (en) Stable active human ob protein compositions and methods
IL141936A0 (en) Antibodies to c3b(1) for delivery of diagnostic and therapeutic agents to cancer cells
EP0821969A3 (en) Medicinal Composition comprising TCF-II
LV12149A (lv) 5-Aizvietoti mikofenolskabes 4-aminoatvasinajumi
NO964688L (no) Ny peptid-aktivsubstans og fremstilling av denne
PT1105503E (pt) Guanililciclase humana soluvel alfal/betal (hsgc alfal/betal) isolada e purificada
HK1035206A1 (en) Delivery of therapeutic proteins via implantation of genetically modified cells in the omentum.
TR199800705T2 (da)
SI1027375T1 (sl) Anti-idiotipska monoklonska protitelesa, njihova uporaba v aktivni imunoterapiji malignih tumorjev in sestavki, ki jih vsebujejo
DE50013908D1 (de) Zytotoxisches t-zellepitop des papillomavirus l1-proteins und seine verwendung in diagnostik und therapie